BIOLASE Announces the Introduction of the Waterlase MDX(TM) Line of All-Tissue Lasers at the Chicago Dental Society Midwinter...
February 24 2012 - 8:00AM
Marketwired
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, today announced that the new
line of Waterlase MDX™ all-tissue lasers was launched this week at
the annual Chicago Dental Society Midwinter Meeting being held
through February 25 (Booth #1237). The new Waterlase MDX lasers
expand the Company's product offerings and complement the
industry-leading Waterlase iPlus™ all-tissue dental laser system.
Two models of the Waterlase MDX are available. The 8-watt
Waterlase MDX 300 improves on BIOLASE's time-tested Waterlase MD
platform with an updated user interface, a new laser engine and a
new lightweight and more flexible titanium fiber cable. The
Waterlase MDX 450 increases the power output to 9-watts and cuts
hard-tissue up to 70 percent faster than the Waterlase MDX 300, but
is still approximately 40 percent slower than the Waterlase
iPlus.
"The new Waterlase MDX again demonstrates our engineering
expertise and ability to design products for all segments of the
global dental market," said Chairman and CEO Federico Pignatelli.
"Our flagship laser, the Waterlase iPlus, is the most advanced
laser ever produced for dentistry and, with its tremendous cutting
speed and graphical intuitive user interface, addresses a wide
range of clinical procedures with more than 50 presets. The new
Waterlase MDX is the logical evolution of the Waterlase MD Turbo,
the best selling all-tissue dental laser in history, and allows us
to offer a blend of features from the Waterlase iPlus and Waterlase
MD in a modernized platform to practitioners that do not require
the advanced speed and functionality of the Waterlase iPlus.
"The Waterlase MDX has been very well received upon its
introduction at the Chicago Midwinter show and we see it adding a
new dimension to our comprehensive line of laser dental products,"
concluded Pignatelli.
Dmitri Boutoussov, Chief Technology Officer, commented, "We
wanted to build on our well established Waterlase MD platform and
integrate our finest laser engine technology to that product. This
allows us to offer the Waterlase MDX in multiple power
configurations to meet the price and performance needs of
specialists such as endodontists and pediatric dentists whose
clinical indications do not require the features and performance of
the Waterlase iPlus."
About BIOLASE Technology, Inc. BIOLASE
Technology, Inc., the World's leading Dental Laser Company, is a
medical technology company that develops, manufactures and markets
dental lasers and also distributes and markets dental imaging
equipment, products that are focused on technologies that advance
the practice of dentistry and medicine. The Company's laser
products incorporate 284 patented and patent pending technologies
designed to provide clinically superior performance with less pain
and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. BIOLASE has sold more
than 19,000 lasers among 16,000 customers. Other products under
development address ophthalmology and other medical and consumer
markets.
For updates and information on laser and Waterlase dentistry,
find BIOLASE at http://www.biolase.com, Twitter at
http://twitter.com/GoWaterlase, and YouTube at
http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within
the meaning of safe harbor provided by the Securities Reform Act of
1995 that are based on the current expectations and estimates by
our management. These forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," and variations of these words or similar expressions.
Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks, uncertainties
and other factors which may cause the Company's actual results to
differ materially from the statements contained herein, and are
described in the Company's reports it files with the Securities and
Exchange Commission, including its annual and quarterly reports. No
undue reliance should be placed on forward-looking statements. Such
information is subject to change, and we undertake no obligation to
update such statements.
For further information, please contact: Jill Bertotti Allen
& Caron +1-949-474-4300 jill@allencaron.com
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Sep 2023 to Sep 2024